Co-Authors
This is a "connection" page, showing publications co-authored by Terry Day and Anand Sharma.
Connection Strength
2.357
-
Elective neck dissection in salivary gland malignancies: Systematic review and meta-analysis. Head Neck. 2022 02; 44(2):505-517.
Score: 0.202
-
The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020. Cancers (Basel). 2020 Jun 11; 12(6).
Score: 0.183
-
Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. Otolaryngol Head Neck Surg. 2018 04; 158(4):649-659.
Score: 0.154
-
Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. Cancer. 2017 Dec 15; 123(24):4841-4850.
Score: 0.150
-
Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer. Cancer. 2017 Jul 15; 123(14):2651-2660.
Score: 0.145
-
Effect of postoperative radiotherapy on survival for surgically managed pT3N0 and pT4aN0 laryngeal cancer: Analysis of the National Cancer Data Base. Cancer. 2017 Jun 15; 123(12):2248-2257.
Score: 0.145
-
Hyperbaric oxygen therapy for the treatment of radiation-induced xerostomia: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jul; 120(1):22-8.
Score: 0.127
-
A comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014 Apr; 140(4):331-7.
Score: 0.119
-
Salivary gland transfer to prevent radiation-induced xerostomia: a systematic review and meta-analysis. Oral Oncol. 2014 Feb; 50(2):77-83.
Score: 0.116
-
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. 2010 Feb; 120(2):236-42.
Score: 0.089
-
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502.
Score: 0.084
-
Proximal esophageal stenosis in head and neck cancer patients after total laryngectomy and radiation. ORL J Otorhinolaryngol Relat Spec. 2008; 70(4):229-35.
Score: 0.079
-
Driving performance in patients with cancer in the head and neck region: a pilot study. Arch Otolaryngol Head Neck Surg. 2007 Sep; 133(9):904-9.
Score: 0.075
-
Management of paranasal sinus malignancy. Curr Treat Options Oncol. 2005 Jan; 6(1):3-18.
Score: 0.063
-
Melanoma of the head and neck. Curr Treat Options Oncol. 2005 Jan; 6(1):19-30.
Score: 0.063
-
Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol. 2005 Jan; 6(1):47-57.
Score: 0.063
-
Salivary gland neoplasms. Curr Treat Options Oncol. 2004 Feb; 5(1):11-26.
Score: 0.059
-
Oral cancer treatment. Curr Treat Options Oncol. 2003 02; 4(1):27-41.
Score: 0.055
-
Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck Cancer. JCO Oncol Pract. 2021 10; 17(10):e1512-e1523.
Score: 0.048
-
Microscopic Extranodal Extension in HPV-Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation. Otolaryngol Head Neck Surg. 2021 10; 165(4):536-549.
Score: 0.048
-
Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2020 12 01; 146(12):1109-1119.
Score: 0.047
-
Barriers to the Delivery of Timely, Guideline-Adherent Adjuvant Therapy Among Patients With Head and Neck Cancer. JCO Oncol Pract. 2020 12; 16(12):e1417-e1432.
Score: 0.046
-
Association of Care Processes With Timely, Equitable Postoperative Radiotherapy in Patients With Surgically Treated Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2018 12 01; 144(12):1105-1114.
Score: 0.041
-
Racial and Ethnic Disparities in Travel for Head and Neck Cancer Treatment and the Impact of Travel Distance on Survival. Cancer. 2018 08 01; 124(15):3181-3191.
Score: 0.040
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.025
-
Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008 Jul; 118(7):1180-5.
Score: 0.020
-
Radiation dose, driving performance, and cognitive function in patients with head and neck cancer. Radiother Oncol. 2008 May; 87(2):304-7.
Score: 0.020
-
Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep. 2007 Mar; 9(2):152-8.
Score: 0.018
-
Role of mitomycin in upper digestive tract stricture. Head Neck. 2007 Jan; 29(1):12-7.
Score: 0.018
-
Laryngeal penetration and aspiration during swallowing after the treatment of advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2005 Jul; 131(7):615-9.
Score: 0.016